Skip to content
lifestyle.social-matic.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tiziana Life Sciences Ltd.
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
July 31, 2026
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
July 22, 2026
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
June 25, 2026
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
June 15, 2026
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
May 28, 2026
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
May 24, 2026
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 24, 2026
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 23, 2026
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
April 16, 2026
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
April 14, 2026
1
2
Next Page
→